{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:35:48Z","timestamp":1777880148462,"version":"3.51.4"},"reference-count":108,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jgo.2026.102964","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T21:16:10Z","timestamp":1775250970000},"page":"102964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A scoping review investigating the influence of comorbidities on the use and outcomes of biological therapies in breast cancer"],"prefix":"10.1016","volume":"17","author":[{"given":"Sophie","family":"Trotter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Crook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda","family":"Wyld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2026.102964_bb0005","series-title":"Cancer incidence for common cancers, cancer statistics","author":"UK CR","year":"2024"},{"key":"10.1016\/j.jgo.2026.102964_bb0010","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/bjs.10885","article-title":"Omission of surgery in older women with early breast cancer has an adverse impact on breast cancer-specific survival","volume":"105","author":"Ward","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.jgo.2026.102964_bb0015","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1040-8428(02)00133-6","article-title":"Factors influencing treatment patterns of breast cancer patients age 75 and older","volume":"46","author":"Hurria","year":"2003","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jgo.2026.102964_bb0020","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1634\/theoncologist.2009-0198","article-title":"How does older age influence oncologists\u2019 cancer management?","volume":"15","author":"Foster","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.jgo.2026.102964_bb0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12877-021-02684-y","article-title":"The dynamics of frailty development and progression in older adults in primary care in England (2006-2017): a retrospective cohort profile","volume":"22","author":"Fogg","year":"2022","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.jgo.2026.102964_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101860","article-title":"Global and regional prevalence of multimorbidity in the adult population in community settings: a systematic review and meta-analysis","volume":"57","author":"Chowdhury","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jgo.2026.102964_bb0035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ccc.2020.08.007","article-title":"The frailty syndrome: a critical issue in geriatric oncology","volume":"37","author":"Minami","year":"2021","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.jgo.2026.102964_bb0040","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/ageing\/26.4.315","article-title":"Unstable disability and the fluctuations of frailty","volume":"26","author":"Campbell","year":"1997","journal-title":"Age Ageing"},{"key":"10.1016\/j.jgo.2026.102964_bb0045","first-page":"5589","article-title":"The impact of frailty on breast cancer outcomes: evidence from analysis of the nationwide inpatient sample, 2005-2018","volume":"12","author":"Tsai","year":"2022","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jgo.2026.102964_bb0050","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0021-9681(70)90054-8","article-title":"The pre-therapeutic classification of comorbidity in chronic disease","volume":"23","author":"Feinstein","year":"1970","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.jgo.2026.102964_bb0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10549-017-4295-4","article-title":"Influence of comorbidity on chemotherapy use for early breast cancer: systematic review and meta-analysis","volume":"165","author":"Edwards","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jgo.2026.102964_bb0060","article-title":"Factors influencing breast cancer outcomes in Australia: a systematic review","volume":"28","author":"Ho-Huynh","year":"2019","journal-title":"Eur J Cancer Care"},{"key":"10.1016\/j.jgo.2026.102964_bb0065","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2318-8-24","article-title":"A standard procedure for creating a frailty index","volume":"8","author":"Searle","year":"2008","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.jgo.2026.102964_bb0070","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41571-022-00687-1","article-title":"Systemic therapy for early-stage breast cancer: learning from the past to build the future","volume":"19","author":"Agostinetto","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0075","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart Martine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2026.102964_bb0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0085","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2026.102964_bb0090","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn Richard","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2026.102964_bb0095","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and Fulvestrant in advanced breast cancer","volume":"379","author":"Turner Nicholas","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2026.102964_bb0100","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with Ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi Gabriel","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2026.102964_bb0105","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with Ribociclib plus Fulvestrant in advanced breast cancer","volume":"382","author":"Slamon Dennis","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2026.102964_bb0110","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with Ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2026.102964_bb0115","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0120","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor\u2013positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2026.102964_bb0125","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2026.102964_bb0130","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2026.102964_bb0135","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt Andrew","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2026.102964_bb0140","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2026.102964_bb0145","article-title":"Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus)","volume":"5","author":"Morgan","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jgo.2026.102964_bb0150","series-title":"Programme Grants for applied research, improving outcomes for women aged 70 years or above with early breast cancer: research programme including a cluster RCT","author":"Wyld","year":"2022"},{"key":"10.1016\/j.jgo.2026.102964_bb0155","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/sj.bjc.6603709","article-title":"Non-standard management of breast cancer increases with age in the UK: a population based cohort of women > or =65 years","volume":"96","author":"Lavelle","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jgo.2026.102964_bb0160","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1200\/JCO.2009.24.3295","article-title":"Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians","volume":"28","author":"Mandelblatt","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103821","article-title":"Chemotherapy in older patients with early breast cancer","volume":"78","author":"Schmidt","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.jgo.2026.102964_bb0170","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/annonc\/mdu540","article-title":"The prevalence and outcomes of frailty in older cancer patients: a systematic review","volume":"26","author":"Handforth","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0175","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.2003.08.010","article-title":"Participation of patients 65 years of age or older in cancer clinical trials","volume":"21","author":"Lewis","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0180","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/jgs.12687","article-title":"Comorbidity burden and guideline-concordant care for breast cancer","volume":"62","author":"Kimmick","year":"2014","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jgo.2026.102964_bb0185","first-page":"337","article-title":"The impact of comorbidity on cancer and its treatment","volume":"66","author":"Sarfati","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jgo.2026.102964_bb0190","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/jnci\/djr188","article-title":"The influence of comorbidities on overall survival among older women diagnosed with breast cancer","volume":"103","author":"Patnaik","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jgo.2026.102964_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2025.102255","article-title":"Age and comorbidity in relation to treatment and survival outcomes in triple-negative breast cancer: a Swedish nationwide registry-based study","volume":"16","author":"Nyqvist-Streng","year":"2025","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2021.100723","article-title":"Conventional cardiac risk factors associated with trastuzumab-induced cardiotoxicity in breast cancer: systematic review and meta-analysis","volume":"45","author":"Koulaouzidis","year":"2021","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.jgo.2026.102964_bb0205","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000659","article-title":"Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials","volume":"5","author":"Eiger","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.jgo.2026.102964_bb0210","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005195","article-title":"Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: a meta-analysis","volume":"95","author":"Jawa","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jgo.2026.102964_bb0215","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00038-019-01270-9","article-title":"Sex differences in comorbidity and frailty in Europe","volume":"64","author":"Ahrenfeldt","year":"2019","journal-title":"Int J Public Health"},{"key":"10.1016\/j.jgo.2026.102964_bb0220","series-title":"Scoping reviews, JBI manual for evidence synthesis","author":"Peters","year":"2020"},{"key":"10.1016\/j.jgo.2026.102964_bb0225","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jgo.2026.102964_bb0230","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/s41416-020-0786-x","article-title":"Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and\/or trastuzumab treatment optimization trial","volume":"122","author":"Eiger","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jgo.2026.102964_bb0235","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10549-020-05915-9","article-title":"Tolerability and toxicity of trastuzumab or trastuzumab+lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D)","volume":"185","author":"Pond\u00e9","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jgo.2026.102964_bb0240","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(18)30083-4","article-title":"Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the elderly task force\/breast cancer group","volume":"19","author":"Wildiers","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104083","article-title":"Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study","volume":"9","author":"Jourdain","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.jgo.2026.102964_bb0250","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.critrevonc.2010.01.002","article-title":"The influences of age and co-morbidities on treatment decisions for patients with HER2-positive early breast cancer","volume":"76","author":"Ring","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jgo.2026.102964_bb0255","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1634\/theoncologist.2009-0056","article-title":"Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER-2+ breast cancer: a survey of oncologists","volume":"14","author":"Hurria","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.jgo.2026.102964_bb0260","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1248\/bpb.b23-00187","article-title":"Real-world predictors of severe neutropenia associated with palbociclib and endocrine therapy for metastatic breast cancer in Japanese patients","volume":"46","author":"Takada","year":"2023","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jgo.2026.102964_bb0265","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.breast.2021.10.010","article-title":"Palbociclib in combination with aromatase inhibitors in patients \u2265 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: a real-world multicentre UK study","volume":"60","author":"El Badri","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.jgo.2026.102964_bb0270","article-title":"Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR(+)\/HER2(\u2212) breast cancer treated with CDK4\/6 inhibitors and endocrine therapy","volume":"12","author":"Tagliaferri","year":"2023","journal-title":"Drugs Context"},{"key":"10.1016\/j.jgo.2026.102964_bb0275","article-title":"Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis","volume":"11","author":"Kanbayashi","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jgo.2026.102964_bb0280","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41523-024-00639-1","article-title":"Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study","volume":"10","author":"Goetz","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.jgo.2026.102964_bb0285","first-page":"851","article-title":"High creatinine level secondary to use of CDK 4\/6 inhibitor treatment (Palbociclib and Ribociclib) + endocrine therapy (ET)","volume":"34","author":"Keskinkilic","year":"2024","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.jgo.2026.102964_bb0290","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13058-024-01902-w","article-title":"Disparities in receipt of 1-st line CDK4\/6 inhibitors with endocrine therapy for treatment of hormone receptor positive, HER2 negative metastatic breast cancer in the real-world setting","volume":"26","author":"Pilehvari","year":"2024","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.jgo.2026.102964_bb0295","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17050818","article-title":"Real-world quality-of-life data in metastatic breast cancer patients treated with CDK4\/6 inhibitors using four assessment tools","volume":"17","author":"Stanciu","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jgo.2026.102964_bb0300","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/annonc\/mdr043","article-title":"First-line bevacizumab-containing therapy for breast cancer: results in patients aged\u226570 years treated in the ATHENA study","volume":"23","author":"Biganzoli","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0305","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10549-018-4828-5","article-title":"Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study","volume":"171","author":"Li","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jgo.2026.102964_bb0310","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1634\/theoncologist.2019-0602","article-title":"Real-world patterns of Everolimus use in patients with metastatic breast cancer","volume":"25","author":"Sharma","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jgo.2026.102964_bb0315","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.sapharm.2014.12.002","article-title":"Treatment patterns among breast cancer patients in the United States using two national surveys on visits to physicians\u2019 offices and hospital outpatient departments","volume":"11","author":"Wittayanukorn","year":"2015","journal-title":"Res Social Adm Pharm"},{"key":"10.1016\/j.jgo.2026.102964_bb0320","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41416-023-02439-z","article-title":"Evidence into practice: a national cohort study of NICE-recommended oncological drug therapy utilisation among women diagnosed with invasive breast cancer in England","volume":"129","author":"Gannon","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jgo.2026.102964_bb0325","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1200\/JCO.2013.48.7884","article-title":"Trastuzumab-related cardiotoxicity among older patients with breast cancer","volume":"31","author":"Chavez-MacGregor","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0330","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1111\/ajco.12766","article-title":"The use of trastuzumab in New Zealand women with breast cancer","volume":"14","author":"Lawrenson","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0335","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.3747\/co.26.4823","article-title":"Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer","volume":"26","author":"Kosalka","year":"2019","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0340","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4048\/jbc.2014.17.4.363","article-title":"Risk of trastuzumab-related cardiotoxicity in early breast cancer patients: a prospective observational study","volume":"17","author":"Xue","year":"2014","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.jgo.2026.102964_bb0345","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10549-008-0260-6","article-title":"Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study","volume":"117","author":"Wadhwa","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jgo.2026.102964_bb0350","doi-asserted-by":"crossref","first-page":"227","DOI":"10.5114\/aoms.2012.28549","article-title":"Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - a prospective study","volume":"8","author":"Piotrowski","year":"2012","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.jgo.2026.102964_bb0355","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdr348","article-title":"Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors","volume":"23","author":"Serrano","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0360","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","article-title":"Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial","volume":"25","author":"Suter","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0365","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cardfail.2011.10.015","article-title":"Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer","volume":"18","author":"Tarantini","year":"2012","journal-title":"J Card Fail"},{"key":"10.1016\/j.jgo.2026.102964_bb0370","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/10781552221076407","article-title":"Prevalence and risk factors of trastuzumab induced cardiotoxicity in Tunisian HER2-positive breast cancer patients","volume":"29","author":"Toukabri","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jgo.2026.102964_bb0375","article-title":"Adjuvant combined therapy with trastuzumab in patients with HER2- positive breast cancer and cardiac alterations: implications for optimal cardio-oncology care","volume":"132","author":"Grela-Wojewoda","year":"2022","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.jgo.2026.102964_bb0380","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/1078155214567162","article-title":"Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: an observational single-centre study","volume":"22","author":"Gunaldi","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jgo.2026.102964_bb0385","first-page":"2569","article-title":"Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab","volume":"33","author":"Lemieux","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jgo.2026.102964_bb0390","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000472","article-title":"Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"3","author":"Ezaz","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jgo.2026.102964_bb0395","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/heartjnl-2012-303151","article-title":"Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors","volume":"99","author":"Farolfi","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.jgo.2026.102964_bb0400","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/1078155220919888","article-title":"Trastuzumab cardiotoxicity in HER2-positive breast cancer patients in tertiary health care center, sultanate of Oman","volume":"27","author":"Alghafar","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jgo.2026.102964_bb0405","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11096-015-0070-y","article-title":"Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital","volume":"37","author":"Ayres","year":"2015","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.jgo.2026.102964_bb0410","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cardfail.2014.05.012","article-title":"Trastuzumab-induced cardiomyopathy: incidence and associated risk factors in an inner-city population","volume":"20","author":"Baron","year":"2014","journal-title":"J Card Fail"},{"key":"10.1016\/j.jgo.2026.102964_bb0415","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10549-014-2836-7","article-title":"Risk of cardiovascular adverse events from trastuzumab (Herceptin(\u00ae)) in elderly persons with breast cancer: a population-based study","volume":"144","author":"Tsai","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jgo.2026.102964_bb0420","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2015.61.8413","article-title":"Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial","volume":"34","author":"Advani","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0425","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3892\/mco.2022.2511","article-title":"Incidence of trastuzumab-induced cardiotoxicity and impact of body mass index in patients with breast cancer: results from a Saudi tertiary cancer center","volume":"16","author":"Al-Saleh","year":"2022","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0430","first-page":"40","article-title":"A prospective cohort study on cardiotoxicity of adjuvant trastuzumab therapy in breast cancer patients","volume":"107","author":"Matos","year":"2016","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.jgo.2026.102964_bb0435","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00432-018-2682-9","article-title":"Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients","volume":"144","author":"Moilanen","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0440","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","article-title":"Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the north central cancer treatment group N9831 adjuvant breast cancer trial","volume":"26","author":"Perez","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0445","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1200\/JCO.2009.23.6950","volume":"28","author":"Russell","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0450","first-page":"68","article-title":"Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer","volume":"10","author":"Vaynrub","year":"2024","journal-title":"Cardiooncology"},{"key":"10.1016\/j.jgo.2026.102964_bb0455","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.breast.2014.05.022","article-title":"Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice","volume":"23","author":"Bonifazi","year":"2014","journal-title":"Breast"},{"key":"10.1016\/j.jgo.2026.102964_bb0460","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.jgo.2020.01.005","article-title":"Initiation of adjuvant chemotherapy and trastuzumab for human epidermal growth receptor 2-positive early invasive breast cancer in a population-based cohort study of older women in England","volume":"11","author":"Gannon","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0465","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2013.51.1261","article-title":"Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study","volume":"32","author":"Vaz-Luis","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0470","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/COC.0000000000000389","article-title":"Prevention of trastuzumab and anthracycline-induced cardiotoxicity using angiotensin-converting enzyme inhibitors or \u03b2-blockers in older adults with breast cancer","volume":"41","author":"Wittayanukorn","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0475","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study","volume":"104","author":"Bowles","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jgo.2026.102964_bb0480","first-page":"7643","article-title":"Comparing trastuzumab-related cardiotoxicity between elderly and younger patients with breast cancer: a prospective cohort study","volume":"25","author":"Aladwani","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jgo.2026.102964_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114309","article-title":"Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: a national population-based cohort study using routine data","volume":"211","author":"Gannon","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jgo.2026.102964_bb0490","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10549-024-07312-y","article-title":"Tolerability and effectiveness of palbociclib in older women with metastatic breast cancer","volume":"206","author":"Baltussen","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jgo.2026.102964_bb0495","series-title":"Trastuzumab use and risk of congestive heart failure in older breast cancer patients","author":"Zhang","year":"2012"},{"key":"10.1016\/j.jgo.2026.102964_bb0500","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s10549-021-06135-5","article-title":"Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study","volume":"187","author":"Tang","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jgo.2026.102964_bb0505","first-page":"1717","article-title":"Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer","volume":"33","author":"Naumann","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jgo.2026.102964_bb0510","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1200\/JCO.2017.74.1165","volume":"35","author":"Ganz","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0515","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00404-019-05185-x","article-title":"Recommendation of adjuvant trastuzumab treatment in HER-2-positive breast cancer patients: insights from quality indicator data collected in certified breast cancer centers in Germany, Italy, Austria, and Switzerland","volume":"300","author":"Inwald","year":"2019","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.jgo.2026.102964_bb0520","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252925","article-title":"Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: a systematic review","volume":"16","author":"Salas","year":"2021","journal-title":"PloS One"},{"key":"10.1016\/j.jgo.2026.102964_bb0525","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1186\/s12877-024-05152-5","article-title":"Frequency of use and characterization of frailty assessments in observational studies on older women with breast cancer: a systematic review","volume":"24","author":"Sanchez","year":"2024","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.jgo.2026.102964_bb0530","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0535","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1093\/annonc\/mdq687","article-title":"EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors","volume":"22","author":"On behalf of the European Organisation for R","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2026.102964_bb0540","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826001189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826001189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:03:09Z","timestamp":1777593789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406826001189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":108,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1879406826001189"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2026.102964","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A scoping review investigating the influence of comorbidities on the use and outcomes of biological therapies in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2026.102964","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102964"}}